Senior Management Team

Tim Edwards | is President and Chief Executive Officer of Cellzome Inc, a privately-owned drug discovery company identifying a new generation of kinase-targeted drugs to treat inflammatory diseases, using its leading Kinobeadstm technology. Previously, Tim had various positions at British Biotech plc including Board Director and Acting CEO, and before that was an Investment Banker in London specialising in the healthcare sector. This followed a 14-year period as an entrepreneur in other industrial sectors, managing and developing three privately-held businesses in which he was a major shareholder.
Tim is a Director of the BioIndustry Association, the trade association for innovative enterprises in the UK's bioscience sector; Chairman of The Mulberry Bush Organisation, a charity founded in 1948 providing therapeutic and residential care for children aged 5-12 with severe emotional and behavioural difficulties; and a Fellow of the RSA, a charity founded in 1754 which drives ideas, innovation and social change. From 2005-2007, Tim was Chairman of ReOx Limited, a biotech company spun out of the University of Oxford by Peter Ratcliffe FRS and others from the Wellcome Trust Centre for Human Genetics. Tim lives in Oxfordshire and is married with 3 sons.

David Simmons | is Chief Scientific Officer at Cellzome. After a successful academic career at several leading research institutions, including the University of Oxford, David joined SmithKline Beecham and later also Celltech, where he was Director of Research, responsible for the NCE drug discovery pipeline. In his last position, before joining Cellzome, David was Vice President, Inflammation Discovery Research at Wyeth Research in Boston, and co-chair of the Inflammation Therapeutic Area Leadership team. In this function, David was responsible for the delivery of innovative pipeline projects and clinical development candidate drugs for inflammatory diseases. David is currently a grant panel reviewer for the UK's Multiple Sclerosis Society and is a reviewer for the Wellcome Trust, Medical Research Council, Leukaemia Research Fund, Cancer Research Campaign and Arthritis Research Campaign.

Jane Dancer | is Vice President of Business Development at Cellzome. Jane has been Director, Business Development at MedImmune Ltd (formerly Cambridge Antibody Technology (CAT)) where she was responsible for negotiating in- and out-licensing activity in relation to CAT's core technology and patents. This included being part of the team that negotiated the major strategic alliance with AstraZeneca that subsequently led to the acquisition of CAT in 2006. Before joining CAT in 2002, Jane was with Aventis Crop Science as a Global Project Manager (2000-2001), and with Agrevo UK Ltd (1990-1999), formerly Schering Agrochemicals Ltd, where she rose to become Team Leader responsible for leading multidisciplinary project teams within the research and early development process. Jane has an MBA from The Judge Institute of Management Studies, University of Cambridge and a PhD in Natural Sciences from the University of Cambridge.

Gerard Drewes | is Vice President of Discovery Research at Cellzome. After obtaining his PhD in Chemistry from the University of Heidelberg and the Max-Planck-Institute for Medical Research, he was a postdoctoral fellow and staff scientist in E. Mandelkow's lab at the Max-Planck-Institute for Structural Molecular Biology in Hamburg. It was here that Gerard discovered the MARK kinases as targets for the treatment of tau pathology in Alzheimer's disease. For this discovery, he was awarded the Boehringer Research Prize in 1998. Since his Habilitation degree in 1999, Gerard is a a lecturer in Biochemistry at the University of Hamburg, and, before joining Cellzome in 2000, he was a Visiting Scientist in the lab of Sir Paul Nurse at the London Cancer Research Institute. Gerard is the author of more than 30 publications mostly in the field of protein kinases and neurobiochemistry.

Richard Hale | is Vice President Development Projects & UK Site Head and is a founder of Cellzome UK. He received his PhD from the University of Cambridge, working on the biochemistry of macrolide biosynthesis with Professor Peter Leadlay. Following a short post-doctoral stay at Cambridge, Richard moved to Glaxo, where over more than ten years he held a number of positions: Starting as a senior scientist in the Natural Products Discovery Department, he subsequently moved to the Biomolecular Structure Unit to become a Group Leader responsible for the Protein & Antibody Expression Group. In 1998, he worked with Walter Blackstock and Malcolm Weir to set up GlaxoWellcome’s CellMap Project.

Gitte Neubauer | is Vice President of Research Operations and a founder of Cellzome. She graduated from Imperial College, London in Biochemistry and worked during that period for Glaxo, both in London and in North Carolina. Gitte completed her PhD thesis with Matthias Mann at the European Molecular Biology Laboratory in Heidelberg in the field of functional proteomics, pioneering the mass spectrometric analysis of protein complexes. At Cellzome, she has been in charge of building and leading the mass spectrometry and IT departments before she was more recently made responsible for research operations and the setting up of the Kinobeads™ screening facility. Gitte is the author of more than 30 scientific publications and a member of the advisory editorial board of the journal Drug Discovery Today. She is a Board of Directors member of BioPro Baden-Württemberg, an agency providing advice and support to the life sciences sector. Gitte is also a member of the industrial advisory board of the Biotechnology faculty of the University of Applied Sciences in Mannheim.

Nigel Ramsden | is Vice President of Drug Discovery at Cellzome. He received his PhD in Chemistry at Oxford University. Whilst a PhD student at Oxford University he designed the molecule later marketed by Oxford GlycoSciences, as Vevesca. Before joining Cellzome, Nigel worked for GlaxoSmithKline, first as Senior Research Chemist and then taking on more and more responsibility within the organization. While at GSK he was involved in the discovery of several drugs, now currently in clinical trials. Nigel led various chemistry teams, giving support to lead identification and optimization projects and a rapid response team, providing rapid solutions for chemical problems. As Director of Genetics Research Portfolio Management he gained broad experience across many therapeutic areas, focusing on proteomics.

Oliver Rausch | is Vice President Biology. He studied Biochemistry at the Freie Universität Berlin before he did his PhD in the laboratory of Prof. Chris Marshall at the Institute of Cancer Research in London. After that Oli joined SmithKlineBeecham (later GlaxoSmithKline), where he was project leader for two kinase drug discovery projects and also a member of the steering committee for global GSK activi- ties in Kinase research. In 2003 Oli joined UCB Celltech and was subsequently promoted to Director of Biology. He was a member of the senior management team of UCB's Inflammation Centre of Excellence and had overall responsibility for developing UCB's future portfolio of innovative small molecule projects for Inflammation. From 2005-2008 he was a member of the Biochemistry and Cell Biology grant review board of the UK Biotechnology and Biological Sciences Research Council (BBSRC), allocating > £ 30 M of research funds annually.

Markus Reinhard | is Vice President of Finance and Administration. Having received a degree in business and administration from the University of Applied Sciences in Ludwigshafen, Germany, he gained wide-spread experience in various aspects of finance during the eleven years whilst working for Knoll AG in Ludwigshafen. He started off as an accountant in the Profitability Calculations Department, quickly becoming responsible for the internal accounting systems for the German-based companies of the group. Markus then moved on to the Controlling Department, rising up over the years to become the financial controller for various Regional- and Business Unit Heads of Knoll. His promotion to Head of the Controlling Department of the largest German affiliate of the Knoll group charged him with the responsibility for controlling, reporting and accounting.